| Literature DB >> 34209863 |
Mostafa A Asmaey1,2, Dennis Abatis1, Ahmed S Abdel-Razek3, George Lambrinidis4, Ioanna Chinou1, Nikolas Fokialakis1, Nikolaos Tsafantakis1, Mohamed Shaaban5, Nektarios Aligiannis1.
Abstract
The fungal strain was isolated from a soil sample collected in Giza province, Egypt, and was identified as Aspergillus ochraceopetaliformis based on phenotypic and genotypic data. The ethyl acetate extract of the fungal strain exhibited promising activity levels against several pathogenic test organisms and through a series of 1H NMR guided chromatographic separations, a new α-pyrone-C-lyxofuranoside (1) along with four known compounds (2-5) were isolated. The planar structure of the new metabolite was elucidated by detailed analysis of its 1D/2D NMR and HRMS/IR/UV spectroscopic data, while the relative configuration of the sugar moiety was determined by a combined study of NOESY and coupling constants data, with the aid of theoretical calculations. The structures of the known compounds-isolated for the first time from A. ochraceopetaliformis-were established by comparison of their spectroscopic data with those in the literature. All isolated fungal metabolites were evaluated for their antibacterial and antifungal activities against six Gram-positive and Gram-negative bacteria as well as against three human pathogenic fungi.Entities:
Keywords: Aspergillus ochraceopetaliformis; C-lyxofuranosides; antimicrobial activity; polyketides; sugar conformations; triterpenoids; α-pyrones
Mesh:
Substances:
Year: 2021 PMID: 34209863 PMCID: PMC8271807 DOI: 10.3390/molecules26133976
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–5.
Figure 2Neighbor-joining phylogenetic tree of the fungal strain ASAI based on 18S rRNA gene sequences, showing its close relationship to Aspergillus spp.
NMR data of 1 (600 MHz, DMSO-d6, δ ppm) a,b.
| Position | 1H ( | 13C | COSY | HMBC | NOESY |
|---|---|---|---|---|---|
| 2 | - | 163.4 | - | - | - |
| 3 | 5.55, d (8.1) | 100.0 | H-4 | C-2, C-4 | H-4 |
| 4 | 7.62, d (8.1) | 142.3 | H-3 | C-2, C-3, C-6, C-1′ | H-3, H-1′, H-2′(w), H-3′, |
| 5 | - | n.d | - | - | - |
| 6 | - | 150.5 | - | - | - |
| 6-OH | 11.22, br.s | - | - | - | H-2′, H-3′ |
| 1′ | 6.00, d (4.5) | 85.1 | H-2′ | C-4, C-6, C-2′ | H-4, H 2′, H 3′(w), H-4′ |
| 2′ | 4.00, br.t (3.6) | 75.2 | H-1′, H-3′ | C-1′, C-3′, C-4′ | H-1′, H 3′, H-4′, 2′-OH, |
| 2′-OH | 5.56, ovlp. | - | H-2′ | - | H-2′, H-3′ |
| 3′ | 3.90, br.t (3.7) | 75.5 | H-2′, H-4′ | C-1′, C-2′, C-4′, C-5′ | H-2′,H-1′,H-4′,H-4, H-5a,b′ |
| 3′-OH | 5.43, br.s | - | H-3′ | - | H-2′, H-3′ |
| 4′ | 3.73, br.q (4.6) | 84.7 | H-5′a, | C-1′, C-3′, C-5′ | H-1′, H-2′, H-3′, |
| 5′a | 3.58, dd (4.6, 11.5)3.62, dd (5.6, 11.5) | 60.7 | H-4′ | C-3′, C-4′ | H-4, H-3′, H-4′ |
| 5′-OH | 5.01, br.s | - | H-5a’,H5b’ | - | H-2′, H-3′ |
a 1H chemical shifts referenced to residual proton (CD2H)SO(CD3) at δ 2.50, followed by multiplicity and coupling constants. 13C chemical shifts referenced to (13CD3)SO(CD3) at δc 39.5. b Assignments were based on HSQC-DEPT, 1H-1H COSY and HMBC experiments recorded in DMSO-d6. nd: not detected.
Figure 31H-1H COSY () and selected key HMBC () correlations for Ochraceopyronide.
Figure 4Tautomerization in Ochraceopyronide (1).
Figure 5Key NOE correlations in Ochraceopyronide (1).
Figure 6(A,B) Theoretical 3JHH coupling constants distribution; (C,D) distribution of 3JHH coupling after MD; (E,F) distribution of furanose conformers of β-d- and β-l-c-lyxofuranoside residues of Ochraceopyronide (1), respectively.
Figure 7Representative conformers (2E for β-d-C-lyxofuranoside (A) and 2T3 for β-l-C-lyxofuranoside (B)) for the two enantiomers of Ochraceopyronide (1).
Antimicrobial activity of the isolated compounds (1–5) (zones of inhibition/MIC mg/mL, n = 3).
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 9/1.19 | 9/1.22 | na | na | na | na | na | na | na |
| 2 | 16/0.10 | 17/0.09 | 12/0.45 | 13/0.50 | 13/0.47 | 13/0.42 | 11 | 12/0.90 | 13/0.72 |
| 3 | 15/0.23 | 16/0.25 | 12/0.52 | 13/0.61 | 13/0.65 | 13/0.47 | 12/0.87 | 12/0.82 | 12/0.7 8 |
| 4 | 8/1.22 | 9/1.15 | na | na | na | na | na | na | na |
| 5 | 10/1.35 | 9/1.25 | 8/1.62 | na | 8/1.97 | 8/1.90 | 9 | 10 | 10 |
| Netilmicin | 20/0.2 × 10−3 | 26 | 21 | 24 | 21 | 23 | nt | nt | nt |
| Amoxicillin | 22 | 24 | 25 | 23 | 22 | 22 | nt | nt | nt |
| 5-fluocytocin | nt | nt | nt | nt | nt | nt | 22 | 22 | 24 |
| AmphotericinB | nt | nt | nt | nt | nt | nt | 24 | 24 | 25 |
na: not active, nt: not tested.